Publications by authors named "Zhengguang He"

8 Publications

  • Page 1 of 1

Catalytic ozonation of 2, 2'-methylenebis (4-methyl-6-tert-butylphenol) over [email protected] dung ash composites: Optimization, toxicity, and degradation mechanisms.

Environ Pollut 2020 Oct 22;265(Pt B):114597. Epub 2020 Apr 22.

School of Water Conservancy & Environment, Zhengzhou University, Zhengzhou 450001, China. Electronic address:

Composite magnetic oxide at cow dung ash, [email protected] dung ash ([email protected]), was used as catalytic material for the degradation of 2, 2'-methylenebis (4-methyl-6-tert-butylphenol) (AO 2246) in real biologically pretreated landfill leachate. The [email protected] composite exhibited catalytic ozonation activity and allowed material separation and magnetic recovery. The effects of several operating parameters including O concentration, catalyst dosage, temperature and scavengers were evaluated in parallel. Over 70% of AO 2246 were removed by the [email protected]/O system under optimum conditions within 120min reaction time. The EPR, GC-MS and free-radical quenching experiments expatiated the mechanism of this degradation process. It was confirmed that the AO 2246 was degraded efficiently in this catalytic micro-ozonation process, Additionally, GC-MS analysis state clearly that the 3,5-bis(1,1-dimethylethyl)phenol, 4-(1,5-dihydroxy-2,6,6-trimethylcyclohex-2-enyl)but-3-en-2-one, ethanone, 1-(1,4-dimethyl-3-cyclohexen-1-yl)-, 5-tert-butyl-6-3, 5-diene-2-one, 2-hydroxyhexanoic acid, 2-propenoic acid 1,1-dimethylethyl ester, butanoic acid, 2-methyl-, methyl ester and propanoic acid, 2, 2-dimethyl- were the dominant oxidation products (OPs) during the degradation of the AO 2246. The EPR results showed that the catalytic ozonation over [email protected] led to produce more hydroxyl radicals, which were in favor of AO 2246 degradation. The toxicity evolution was also performed through a QSAR analysis calculated by the ECOSAR program which further demonstrated the different responses toward the AO 2246 and its OPs.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.envpol.2020.114597DOI Listing
October 2020

FeO nanoparticles loading on cow dung based activated carbon as an efficient catalyst for catalytic microbubble ozonation of biologically pretreated coal gasification wastewater.

J Environ Manage 2020 Aug 29;267:110615. Epub 2020 Apr 29.

Key Laboratory of Recycling and Eco-treatment of Waste Biomass of Zhejiang Province, Zhejiang University of Science and Technology, Hangzhou, 310023, China.

Cow dung based activated carbon was successfully modified by FeO nanoparticles as the novel catalyst (FeO [email protected]) to improve the microbubble ozonation treating biologically pretreated coal gasification wastewater (BPCGW). When the pH, ozone dosage, ozone bubble diameter and catalyst dosage of the ozonation were 7, 0.4 L/min, 5 μm and 3 g/L, the chemical oxygen demand (COD) removal efficiency reached 74% and the ratio of biochemical oxygen demand in five days/COD (BOD/COD) increased from 0.04 to 0.52, which were attributed to the electron transfer of Fe and Fe in FeO and enhanced hydroxyl radicals generation by the reaction of iron ions and ozone. Meanwhile, benzene derivatives, naphthalene and aromatic proteins were significantly removed while multiple chain hydrocarbons and their derivatives composed the main residual organic matters. The catalytic activity was slightly decreased even the catalyst has been reused for five times. Therefore, catalytic microbubble ozonation using FeO [email protected] represented excellent performance treating BPCGW and it is a promising process for wastewater advanced treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jenvman.2020.110615DOI Listing
August 2020

Post hoc analysis of initial treatments and control status in the INITIAL study: an observational study of newly diagnosed patients with asthma.

BMC Pulm Med 2020 Apr 9;20(1):87. Epub 2020 Apr 9.

Department of Respiratory Diseases, Qingdao Municipal Hospital, Qingdao, 266000, China.

Background: The 12-week, multicentre, observational INITIAL study (NCT02143739) assessed asthma severity in newly diagnosed Chinese patients.

Methods: Post hoc analysis of medication combinations prescribed per routine clinical practice at baseline, and the impact on control levels evaluated using 2012 vs 2018 Global Initiative for Asthma (GINA) criteria.

Results: In total, 4491 patients were included in the analysis. At baseline, intermittent, mild, moderate and severe asthma was reported in 3.9, 12.0, 22.6 and 61.6% of patients, respectively. Most patients (90.2%) were prescribed inhaled corticosteroid/long-acting β agonist (ICS/LABA). ICS/LABA plus ≥1 additional medication(s) was prescribed to 66.7% of patients, with leukotriene receptor antagonist (LTRA, 54.7%) being the most common additional medication. Distribution of ICS/LABA vs ICS/LABA+LTRA was comparable in patients with intermittent (3.2% vs 3.0%), mild (11.5% vs 9.7%), moderate (21.2% vs 19.9%) and severe asthma (64.1% vs 67.4%). Control levels among patients using ICS/LABA+LTRA vs ICS/LABA were comparable using GINA 2012 and lower using GINA 2018 criteria. The proportion of patients using ICS/LABA+LTRA vs ICS/LABA with intermittent, mild, moderate and severe asthma controlled at Week 12 (using GINA 2012) were 78.1% vs 80.0, 86.5% vs 85.8, 78.5% vs 71.3, and 59.6% vs 61.8%, respectively. Using GINA 2018 criteria proportions were 86.8% vs 95.9, 86.1% vs 93.2, 82.1% vs 85.3, and 71.9% vs 77.6%, respectively.

Conclusions: Asthma control was not improved by adding LTRA to ICS/LABA and may have been unnecessary for some newly diagnosed patients. These findings were irrespective of the GINA criteria (2012 vs 2018) used and baseline severity.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12890-020-1069-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147012PMC
April 2020

Frequency of Signs and Symptoms in Persons With Asthma.

Respir Care 2020 Feb 29;65(2):252-264. Epub 2019 Oct 29.

Institution of Respiratory Disease, Xinqiao Hospital of 3rd Military Medical University, Chongqing, China.

Background: Signs and symptoms of asthma are well established; however, no study has been performed to rank them. Therefore, we performed this systematic review and meta-analysis to determine the pooled frequencies of different signs and symptoms of asthma in subjects age ≥ 14 y to develop a patient-specific questionnaire.

Methods: Specific search queries were developed to include records published in Embase, PubMed, Cochrane Library, and Google Scholar, until November 2016. We planned to include randomized controlled trials (RCTs) and observational studies for determining the pooled proportions of signs and symptoms and association between combination of symptoms and asthma severity in subjects age ≥ 14 y. The quality assessment was performed using 3 parameters: reported number or percentage of subjects with asthma symptoms, respiratory disorder history, and method for data collection.

Results: Of the 4,939 records retrieved, 67 observational studies ( = 57,033 subjects; age ≥ 14 y) were considered eligible for inclusion in the analysis. A total of 10 symptoms were reported across the studies, with pooled proportions of nasal congestion, sleep disturbances, breathlessness, chest tightness, and wheezing being 61.57%, 56.56%, 50.31%, 50.41%, and 46.97%, respectively. In records of medical history, the pooled proportion of rhinitis was 76.37%, followed by allergy/atopy at 63.53%. The pooled proportion of asthma medication use was 83.27%. In terms of the symptom combinations, the combination of wheezing, breathlessness, chest tightness, and cough was reported in 71.26% of subjects from 4 studies ( = 12,014 subjects). Nasal congestion, sleep disturbance, and chest tightness were the most common symptoms of asthma, followed by wheezing and breathlessness with a combination of symptoms (ie, wheezing, breathlessness, chest tightness, and cough) affecting the highest proportion of subjects.

Conclusions: Asthma severity was dependent on variety of symptoms, consisting mostly of wheezing, breathlessness, chest tightness, and cough. On the basis of our analysis, we recommend a combination of symptoms be included in diagnostic-based questionnaires to aid early diagnosis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4187/respcare.06714DOI Listing
February 2020

INITIAL - An observational study of disease severity in newly diagnosed asthma patients and initial response following 12 weeks' treatment.

Sci Rep 2019 02 4;9(1):1254. Epub 2019 Feb 4.

Department of Respiratory Diseases, Qingdao Municipal Hospital, Qingdao, China.

In China, there are an estimated 30 million people with asthma, a condition that remains poorly controlled in many patients. The INITIAL study (NCT02143739) was a 12-week, multicentre, prospective, observational study comprising 45 centres across Northern and Southern China that aimed to assess asthma severity among newly diagnosed patients as well as their prescribed medications and response to treatment. The primary objective was to evaluate asthma severity using Global Initiative for Asthma (GINA) 2006 research criteria. Secondary objectives included the distribution of asthma medication by GINA severity category and evaluation of GINA 2012-defined control levels. Medications were prescribed as per usual clinical practice. At baseline, among 4491 patients, 3.9%, 12.0%, 22.6% and 61.6% had intermittent, mild persistent, moderate persistent and severe persistent asthma, respectively. Inhaled corticosteroid/long-acting β agonist was the most common initial therapy in 90.2% of patients. GINA 2012-defined controlled asthma levels increased in all groups, rising from 6.1% at baseline to 43.0%, 53.8% and 67.8% at Weeks 4, 8 and 12, respectively. Most patients presented with severe persistent asthma. Newly diagnosed patients with asthma could benefit from at least 3 months of regular treatment followed by long-term pharmacological management.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-36611-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362102PMC
February 2019

Catalytic micro-ozonation by FeO nanoparticles @ cow-dung ash for advanced treatment of biologically pre-treated leachate.

Waste Manag 2019 Jan 3;83:23-32. Epub 2018 Nov 3.

School of Water Conservancy & Environment, Zhengzhou University, Zhengzhou 450001, China. Electronic address:

In this work, the biologically pre-treated leachate was subjected to catalytic micro-ozonation using cow-dung ash composites loaded with FeO nanoparticles ([email protected]) as the catalyst. The optimal conditions used were [email protected] dosage of 0.8 g/L, input ozone of 3.0 g/L, and reaction time of 120 min. This environment yielded the following results: The COD and color number (CN) removal reached 53% and 89%, respectively, and the BOD/COD increased from 0.05 to 0.32. The catalytic micro-ozonation partially degraded the refractory substances into intermediates with lower molecular weight. The percentage of phenolic compounds decreased sharply from 28.08% to 8.56%, largely due to the opening of the ring as well as to the formation of organic intermediates with a low molecular weight. Based on the results culled from the electron paramagnetic resonance (EPR), it is evident that the [email protected] catalyst can accelerate in order to generate OH. This was the main mechanism involved in its excellent ability to degrade refractory pollutants. These results demonstrated the potential use of [email protected] as a catalyst in the catalytic micro-ozonation process.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wasman.2018.10.045DOI Listing
January 2019

Treatment of stabilized landfill leachate by Fenton-like process using FeO particles decorated Zr-pillared bentonite.

Ecotoxicol Environ Saf 2018 10 15;161:489-496. Epub 2018 Jun 15.

School of Water Conservancy & Environment, Zhengzhou University, Zhengzhou 450001, China.

FeO particles decorated Zr pillared bentonite (FeO/Zr-B) were successfully synthesized, which were used to treat stabilized landfill leachate by Fenton-like process. The organics removal and biodegradability were both significantly improved owing to good catalytic stability of the magnetically recoverable catalyst. With the catalyst dosage of 1.0 mg L, initial pH of 2 and peroxide concentration of 0.1 mmol L, the COD removal efficiency increased to 68% and BOD/COD of 0.27 was achieved. According to the results of the GC-MS, Fenton-like reaction with FeO/Zr-B had an excellent removal performance for almost all the heterocyclic compounds. The 3D-EEM fluorescence spectra indicated that the fluorescence intensity was dramatically reduced and the UV humic-like and fulvic-like substances were removed effectively during the catalytic degradation. It seemed advisable to implement this process as a pre-treatment to facilitate the further biological treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ecoenv.2018.06.031DOI Listing
October 2018

Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.

J Infect Dis 2018 05;217(11):1708-1717

Department of Pulmonary and Critical Care Medicine, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China.

Background: Data are limited on the impact of neuraminidase inhibitor (NAI) treatment on avian influenza A(H7N9) virus RNA shedding.

Methods: In this multicenter, retrospective study, data were collected from adults hospitalized with A(H7N9) infection during 2013-2017 in China. We compared clinical features and A(H7N9) shedding among patients with different NAI doses and combination therapies and evaluated factors associated with A(H7N9) shedding, using Cox proportional hazards regression.

Results: Among 478 patients, the median age was 56 years, 71% were male, and 37% died. The median time from illness onset to NAI treatment initiation was 8 days (interquartile range [IQR], 6-10 days), and the median duration of A(H7N9) RNA detection from onset was 15.5 days (IQR, 12-20 days). A(H7N9) RNA shedding was shorter in survivors than in patients who died (P < .001). Corticosteroid administration (hazard ratio [HR], 0.62 [95% confidence interval {CI}, .50-.77]) and delayed NAI treatment (HR, 0.90 [95% CI, .91-.96]) were independent risk factors for prolonged A(H7N9) shedding. There was no significant difference in A(H7N9) shedding duration between NAI combination treatment and monotherapy (P = .65) or between standard-dose and double-dose oseltamivir treatment (P = .70).

Conclusions: Corticosteroid therapy and delayed NAI treatment were associated with prolonged A(H7N9) RNA shedding. NAI combination therapy and double-dose oseltamivir treatment were not associated with a reduced A(H7N9) shedding duration as compared to standard-dose oseltamivir.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiy115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679685PMC
May 2018
-->